Skip to content
Search

Latest Stories

NPA supports FSRH's appeal to Wes Streeting to prioritise women's reproductive health

NPA supports FSRH's appeal to Wes Streeting to prioritise women's reproductive health
NPA says community pharmacies have played a vital role in providing easy, affordable care for women and girls, providing advice and access to emergency contraception in a safe and non judgemental environment

In an open letter published by the Faculty of Sexual and Reproductive Healthcare (FSRH), President, Dr. Janet Barter, has appealed to the newly appointed Health Secretary of the State, Wes Streeting for urgent prioritisation of women's reproductive health.

Signed by 800 clinicians and supported by 65 endorsing organisations, the letter underscores the rising issues around women's reproductive health.


Dr. Barter’s letter highlights significant health inequalities affecting women across the UK, including rising rates of teenage pregnancy and a stark disparity in maternal mortality among Black and ethnic minority women.

"There are increasing rates of teenage pregnancy across England and Wales,1 and women from the most deprived backgrounds are almost three times more likely to need abortions than women from the wealthiest backgrounds," Dr. Barter said.

"Shamefully, maternal mortality for Black women is also currently almost four times higher than for White women and significant disparities also exist for women of Asian and mixed ethnicity.

"These inequalities are unacceptable but importantly preventable with the right policies in place," she continued.

Alluding to the Labour Party's election manifesto pledge to ensure women's health, the letter outlines the FSRH Hatfield Vision—a comprehensive framework for improving sexual and reproductive health services.

The Vision includes goals such as better access to contraception, enhanced education, and a dedicated sexual and reproductive health strategy.

Gary Waltham, CEO at FSRH, echoed the call to action, stressing the importance of accessible sexual and reproductive healthcare.

Dr. Aziza Sesay, the FSRH Hatfield Vision Ambassador, highlighted the daily impact of health inequities on women and girls, particularly in deprived communities. "Action to tackle these health inequities is crucial and must be a priority for this government."

In a notable endorsement, the National Pharmacy Association (NPA) also joined the appeal.

Gareth Jones, NPA’s Director of External Affairs, emphasised the vital role of community pharmacies in providing reproductive health services.

"We're pleased to join a wide range of organisations in calling on the new government to improve access to sexual and reproductive health services for women and girls.

"The NPA have long supported ambitions in the Hatfield Vision on women's health and urge the new government to implement it as a priority.
"Community pharmacies have played a vital role in providing easy, affordable care for women and girls, including providing advice and access to emergency contraception in a safe and non judgemental environment.
"That is why we want to see the introduction of a dedicated Sexual and Reproductive Health Strategy and a commitment to continuing the Women’s Health Strategy, which will help to tackle health inequalities and widen access to services," he said.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less